Saturday, December 26, 2009

Definity


Definity is a brand name of perflutren, approved by the FDA in the following formulation(s):


DEFINITY (perflutren - injectable; intravenous)



  • Manufacturer: LANTHEUS MEDCL

    Approval date: July 31, 2001

    Strength(s): 6.52MG/ML [RLD]

Has a generic version of Definity been approved?


No. There is currently no therapeutically equivalent version of Definity available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Definity. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
    Patent 5,527,521
    Issued: June 18, 1996
    Inventor(s): Unger; Evan C.
    Assignee(s): ImaRx Pharmaceutical Corp.
    Substantially homogeneous aqueous suspensions of low density microspheres are presented as contrast media for imaging the gastrointestinal tract and other body cavities using computed tomography. In one embodiment, the low density microspheres are gas-filled. With computed tomography, the contrast media serve to change the relative density of certain areas within the gastrointestinal tract and other body cavities, and improve the overall diagnostic efficacy of this imaging method.
    Patent expiration dates:

    • February 22, 2015
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING
      ✓ 
      Drug product




  • Method of preparing gas and gaseous precursor-filled microspheres
    Patent 5,585,112
    Issued: December 17, 1996
    Inventor(s): Unger; Evan C. & Fritz; Thomas A. & Matsunaga; Terry & Ramaswami; VaradaRajan & Yellowhair; David & Wu; Guanli
    Assignee(s): ImaRx Pharmaceutical Corp.
    Methods of and apparatus for preparing temperature activated gaseous precursor-filled liposomes are described. Gaseous precursor-filled liposomes prepared by these methods are particularly useful, for example, in ultrasonic imaging applications and in therapeutic drug delivery systems.
    Patent expiration dates:

    • December 17, 2013
      ✓ 
      Drug product




  • Methods for diagnostic imaging by regulating the administration rate of a contrast agent
    Patent 6,033,645
    Issued: March 7, 2000
    Inventor(s): Unger; Evan C. & Matsunaga; Terry & Fritz; Thomas A. & Ramaswami; Varadarajan
    Methods for providing an image of an internal region of a patient. Embodiments of the methods involve administering to the patient a contrast agent which comprises a vesicle composition comprising, in an aqueous carrier, a gas or gaseous precursor and vesicles comprising lipids, proteins or polymers. The patient is scanned using diagnostic imaging, such as ultrasound, to obtain a visible image of the region. The contrast agent is administered to the patient at a rate to substantially eliminate diagnostic artifacts in the image. The methods are particularly useful for diagnosing the presence of any diseased tissue in the patient.
    Patent expiration dates:

    • June 19, 2016
      ✓ 
      Patent use: METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING



See also...

  • Definity Consumer Information (Wolters Kluwer)
  • Definity Advanced Consumer Information (Micromedex)
  • Perflutren (Lipid Microspheres) Consumer Information (Wolters Kluwer)
  • Perflutren (Protein-Type A Microspheres) Consumer Information (Wolters Kluwer)
  • Perflutren lipid microsphere Intravenous Advanced Consumer Information (Micromedex)
  • Perflutren protein type a microsphere Intravenous Advanced Consumer Information (Micromedex)

Friday, December 25, 2009

Cough Medications


Definition of Cough: A rapid expulsion of air from the lungs typically in order to clear the lung airways of fluids, mucus, or material.

Drugs associated with Cough

The following drugs and medications are in some way related to, or used in the treatment of Cough. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Cough

  • Cough and Nasal Congestion (596 drugs)

Learn more about Cough





Drug List:

Tuesday, December 22, 2009

Neluos




Neluos may be available in the countries listed below.


Ingredient matches for Neluos



Oxybutynin

Oxybutynin hydrochloride (a derivative of Oxybutynin) is reported as an ingredient of Neluos in the following countries:


  • Japan

International Drug Name Search

Alvesco


Alvesco is a brand name of ciclesonide, approved by the FDA in the following formulation(s):


ALVESCO (ciclesonide - aerosol, metered; inhalation)



  • Manufacturer: NYCOMED US

    Approval date: January 10, 2008

    Strength(s): 0.08MG/INH, 0.16MG/INH [RLD]

Has a generic version of Alvesco been approved?


No. There is currently no therapeutically equivalent version of Alvesco available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alvesco. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions
    Patent 5,482,934
    Issued: January 9, 1996
    Inventor(s): Calatayud; Jose & Conde; Jose R. & Luna; Manuel
    Assignee(s): Especialidades Latinas Medicamentos Universales, S.A. (Elmu, S.A.)
    The present invention relates to compounds of the formula: ##STR1## in which X.sub.1 and X.sub.2 correspond to H or F without distinction; R.sub.1 represents the following radicals: ##STR2## and R.sub.2 represents the radicals ##STR3## in the form of an R epimer, an S epimer, or a stereoisomeric mixture of the R and S epimers in terms of the orientation of the substituents on the carbon atom at position 22, novel intermediates and a method of their preparation by hydrolysis-ketalization, and use of such compounds as drugs and/or therapeutic agents.
    Patent expiration dates:

    • October 24, 2017
      ✓ 
      Patent use: METHOD OF TREATING INFLAMMATORY CONDITIONS
      ✓ 
      Drug substance
      ✓ 
      Drug product




  • Medicinal aerosol formulations
    Patent 5,605,674
    Issued: February 25, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:

    • February 25, 2014
      ✓ 
      Drug product




  • Medicinal aerosol formulations
    Patent 5,683,677
    Issued: November 4, 1997
    Inventor(s): Purewal; Tarlochan S. & Greenleaf; David J.
    Assignee(s): Riker Laboratories, Inc.
    A self-propelling aerosol formulation which may be free from CFC's which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.
    Patent expiration dates:

    • November 4, 2014
      ✓ 
      Drug product




  • Seal configuration for aerosol canister
    Patent 5,775,321
    Issued: July 7, 1998
    Inventor(s): Alband; Todd D.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A dual seal configuration for an aerosol canister containing a medicinal aerosol formulation. The canister includes a vial body and valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation. The dual seal configuration reduces leakage of contents, and is particularly helpful where the formulation includes hydrofluorocarbon propellant and an ethanol cosolvent. The first seal can be selected to be a barrier to the formulation components, while the second seal can be relatively more labile to such components.
    Patent expiration dates:

    • July 7, 2015
      ✓ 
      Drug product




  • Device for delivering an aerosol
    Patent 6,006,745
    Issued: December 28, 1999
    Inventor(s): Marecki; Paul E.
    Assignee(s): Minnesota Mining and Manufacturing Company
    A device for delivering an aerosol comprises a casing member, a valve stem, and a sealing member, wherein the sealing member comprises a thermoplastic elastomer comprising of a copolymer of about 80-95 mole % ethylene and about 5-20 mole % of at least one comonomer wherein the comonomer(s) are 1-butene, 1-hexene, or 1-octene. The device is used with pharmaceutical formulations containing 1,1,1,2-tetrafluoroethane and/or 1,1,1,2,3,3,3-heptafluoropropane as the propellant.
    Patent expiration dates:

    • December 28, 2016
      ✓ 
      Drug product




  • Seal configuration for aerosol canister
    Patent 6,036,942
    Issued: March 14, 2000
    Inventor(s): Alband; Todd D.
    Assignee(s): 3M Innovative Properties Company
    An aerosol canister for containing a medicinal aerosol formulation. The canister involves a vial body and a valve ferrule sealed by first and second sealing members to form a chamber that contains the medicinal aerosol formulation.
    Patent expiration dates:

    • April 30, 2013
      ✓ 
      Drug product




  • Medicinal aerosol products containing formulations of ciclesonide and related steroids
    Patent 6,120,752
    Issued: September 19, 2000
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company
    Byk Gulden Lomberg Chemische Fabrik GmbH
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:

    • May 13, 2018
      ✓ 
      Drug product




  • Medicinal aerosol formulation of ciclesonide and related compounds
    Patent 6,264,923
    Issued: July 24, 2001
    Inventor(s): Oliver; Martin J. & Fatania; Kanu M. & Scott; John S. & Muller; Helgert
    Assignee(s): 3M Innovative Properties Company
    A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl and R.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations also include hydrofluorocarbon propellants such as HFC 134a and/or 227, and cosolvent such as ethanol in an amount sufficient to solubilize the ciclesonide or related steroid (and various optional ingredients, such as surfactant). The formulations exhibit very desirable physical and chemical stability, as well as excellent delivery characteristics.
    Patent expiration dates:

    • May 13, 2018
      ✓ 
      Drug product



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • January 10, 2011 - NEW DOSAGE FORM

    • October 20, 2011 - NEW CHEMICAL ENTITY

See also...

  • Alvesco Consumer Information (Drugs.com)
  • Alvesco Aerosol Consumer Information (Wolters Kluwer)
  • Alvesco HFA inhalation Consumer Information (Cerner Multum)
  • Alvesco inhalation Consumer Information (Cerner Multum)
  • Alvesco Advanced Consumer Information (Micromedex)
  • Ciclesonide Aerosol Consumer Information (Wolters Kluwer)
  • Ciclesonide inhalation Consumer Information (Cerner Multum)
  • Ciclesonide Inhalation Advanced Consumer Information (Micromedex)

Friday, December 18, 2009

Defencare




Defencare may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Defencare



Permethrin

Permethrin is reported as an ingredient of Defencare in the following countries:


  • Germany

  • Netherlands

  • United Kingdom

International Drug Name Search

Thursday, December 17, 2009

Selsun Gold




Ingredient matches for Selsun Gold



Selenium Sulfide

Selenium Sulfide is reported as an ingredient of Selsun Gold in the following countries:


  • United States

International Drug Name Search

Wednesday, December 9, 2009

Humalog Mix 75 / 25


See also: Generic Humalog Mix 50/50, Generic Humalog Mix 50/50 KwikPen, Generic Humalog Mix 50/50 Pen, Generic Humalog Mix 75/25 KwikPen, Generic Humalog Mix 75/25 Pen


Humalog Mix 75/25 is a brand name of insulin lispro/insulin lispro protamine, approved by the FDA in the following formulation(s):


HUMALOG MIX 75/25 (insulin lispro protamine recombinant; insulin lispro recombinant - injectable; injection)



  • Manufacturer: LILLY

    Approval date: December 22, 1999

    Strength(s): 75 UNITS/ML;25 UNITS/ML [RLD]

Has a generic version of Humalog Mix 75/25 been approved?


No. There is currently no therapeutically equivalent version of Humalog Mix 75/25 available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Humalog Mix 75/25. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Monomeric insulin analog formulations
    Patent 5,461,031
    Issued: October 24, 1995
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analog formulations
    Patent 5,474,978
    Issued: December 12, 1995
    Inventor(s): Bakaysa; Diane L. & Brems; David N. & Frank; Bruce H. & Havel; Henry A. & Pekar; Allen H.
    Assignee(s): Eli Lilly and Company
    The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Patent expiration dates:

    • June 16, 2014




  • Insulin analogs modified at position 29 of the B chain
    Patent 5,514,646
    Issued: May 7, 1996
    Inventor(s): Chance; Ronald E. & DiMarchi; Richard D. & Frank; Bruce H. & Shields; James E.
    Analogs of human insulin modified at position 29 of the B chain thereof and, optionally, at other positions, have modified physico-chemical and pharmacokinetic properties and are useful in the treatment of hyperglycemia.
    Patent expiration dates:

    • May 7, 2013




  • Monomeric insulin analog formulations
    Patent 5,747,642
    Issued: May 5, 1998
    Inventor(s): De Felippis; Michael R.
    Assignee(s): Eli Lilly and Company
    The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Patent expiration dates:

    • June 16, 2014



See also...

  • HumaLog Mix 75/25 Vials Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Pens Consumer Information (Wolters Kluwer)
  • Humalog Mix 75/25 Consumer Information (Cerner Multum)
  • Humalog Mix 75/25 Advanced Consumer Information (Micromedex)
  • Humalog Mix Consumer Information (Drugs.com)
  • Insulin Lispro Protamine/Insulin Lispro Pens Consumer Information (Wolters Kluwer)
  • Insulin Lispro Protamine/Insulin Lispro Vials Consumer Information (Wolters Kluwer)
  • Insulin lispro and insulin lispro protamine Consumer Information (Cerner Multum)
  • Insulin lispro protamine and insulin lispro Subcutaneous Advanced Consumer Information (Micromedex)

Tuesday, December 8, 2009

EnaLich comp




EnaLich comp may be available in the countries listed below.


Ingredient matches for EnaLich comp



Enalapril

Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of EnaLich comp in the following countries:


  • Germany

Hydrochlorothiazide

Hydrochlorothiazide is reported as an ingredient of EnaLich comp in the following countries:


  • Germany

International Drug Name Search

Monday, December 7, 2009

Ketotifen




Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

R06AX17,S01GX08

CAS registry number (Chemical Abstracts Service)

0034580-13-7

Chemical Formula

C19-H19-N-O-S

Molecular Weight

309

Therapeutic Categories

Antiasthmatic agent

Antiallergic agent

Histamine, H₁-receptor antagonist

Chemical Name

10H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-

Foreign Names

  • Ketotifenum (Latin)
  • Ketotifen (German)
  • Kétotifène (French)
  • Ketotifeno (Spanish)

Generic Names

  • Ketotifen (OS: BAN)
  • Ketotifene (OS: DCIT)
  • Kétotifène (OS: DCF)
  • Ketotifen Fumarate (OS: USAN, JAN, BANM)
  • HC 20 511 nfu (IS)
  • HC 20-511 (IS)
  • Ketotifenhydrogenfumarat (IS)
  • Ketotifen Fumarate (PH: BP 2010)
  • Ketotifen Hydrogen Fumarate (PH: Ph. Eur. 6)
  • Ketotifeni hydrogenfumaras (PH: Ph. Eur. 6)

Brand Names

  • Alaway
    Bausch & Lomb, United States


  • Alerfast
    Aversi, Georgia


  • Astafen
    Sandoz, Turkey


  • Asthafen
    Torrent, India; Torrent, Myanmar


  • Blasket
    Blaskov, Colombia


  • Cosolve
    Vargas, Venezuela


  • Dhatifen
    DHA, Singapore


  • Difen
    Biogen, Colombia


  • Dihalar
    Krka, Slovenia


  • Frenasma
    Faran, Romania


  • Galitifen
    Galenika, Serbia


  • Histofen
    Riyad Pharma, Oman; Riyadh, Bahrain


  • K-Asmal
    Silanes, Guatemala; Silanes, Nicaragua


  • K-Drops
    Alapis Pharma, Greece


  • Ketifen
    Farqui, Dominican Republic


  • Ketin
    Opalia, Tunisia


  • Ketobron
    Farmacoop, Colombia


  • Ketonil
    Ram Pharmaceutical, Oman; Roemmers, Peru


  • Ketotifen Actavis
    Actavis, Lithuania


  • Ketotifen Help
    Help, Greece


  • Ketotifen LPH
    Labormed Pharma, Romania


  • Ketotifen
    Actavis, Georgia; GMP, Georgia; Hasco, Poland; Polfa Warszawa, Lithuania


  • Ketotifeno Ecar
    Ecar, Colombia


  • Ketotifeno Farmindustria
    Farmindustria, Peru


  • Ketotifeno Genfar
    Genfar, Colombia; Genfar, Ecuador; Genfar, Peru


  • Ketotifeno La Santé
    La Sante, Peru; La Santé, Colombia


  • Ketotifeno MK
    McKesson, Ecuador; MK, Colombia


  • Ketotifeno Terbol
    Terbol, Peru


  • Ketotifeno
    AZ Pharma, Colombia; Medicalex, Colombia; Pentacoop, Colombia; Synthesis, Colombia


  • Ketotiphen
    BHFZ, Georgia


  • Ketotisin
    Chemopharma, Chile; Dollder, Venezuela


  • Loristat
    Farmacoop, Colombia


  • Oftaler
    Saval Nicolich, Chile


  • Tefanyl
    Saiph, Tunisia; Simed, Tunisia


  • Totinal
    Hikma, United Arab Emirates; Hikma, Bahrain; Hikma, Egypt; Hikma, Iraq; Hikma, Jordan; Hikma, Kuwait; Hikma, Lebanon; Hikma, Libya; Hikma, Oman; Hikma, Qatar; Hikma, Saudi Arabia; Hikma, Sudan; Hikma, Syria; Hikma, Yemen


  • Zaditen Oft.
    Novartis Ophthalmics, Peru


  • Zaditen
    Adcock Ingram Pharmaceuticals, South Africa; Defiante, Luxembourg; Novartis, Taiwan; Novartis, Yemen


  • Zasten
    Novartis, Spain


  • Adco-Ketotifen
    Adcock Ingram Pharmaceuticals, South Africa


  • Adco-Zetofen
    Adcock Ingram Pharmaceuticals, South Africa


  • Aerofen
    Silva, Bangladesh


  • Alarid
    Square, Bangladesh


  • Alaway
    Bausch & Lomb, United States


  • Allerket
    Pulitzer, Italy


  • Amitone
    Unison, Sri Lanka; Unison, Singapore


  • Anatifen
    Kobayashi Kako, Japan


  • Antilerg
    Valeant, Argentina


  • Apo-Ketotifen
    Apotex, Guyana


  • Asdron
    Marjan, Brazil


  • Asmafen
    Pan Pharma, Sri Lanka; Xepa-Soul Pattinson, Hong Kong


  • Asmafort
    Julphar, Bahrain; Julphar, Oman


  • Asmalergin
    Merck, Brazil


  • Asmen
    Farmalab, Brazil


  • Astifen
    Kalbe Farma, Sri Lanka


  • Asumalife
    Yung Shin, Singapore


  • Beatifen
    Beacons, Singapore


  • Benanza
    Isei, Japan


  • Benapy
    Sandoz, Japan


  • Bentifen
    Novartis, Italy


  • Bilozen
    Klonal, Argentina


  • Broncoten
    Farmion, Brazil


  • Butifeno
    Bruluart, Mexico


  • Chetofen
    B&G, Italy


  • Chetotifene Mylan
    Mylan, Italy


  • Cipanfeno
    Cipan, Portugal


  • Cratifen
    Kyowa Yakuhin, Japan


  • Denerel
    Medochemie, Bangladesh; Medochemie, Slovakia; Medochemie, Taiwan


  • Dezuwart
    Yoshindo, Japan


  • Dihalar
    Krka, Croatia (Hrvatska)


  • Dovidin
    Anfarm, Greece


  • Drakern
    Nichi-Iko PharmaceuticalJMA, Japan


  • Ecradin
    Med-One, Greece


  • Electer
    Mylan Pharmaceutical, Japan


  • Erliten
    Malaysia Chemist, Singapore


  • Eucycline
    Demo, Greece


  • Fenat
    Drug International, Bangladesh


  • Fental Nexus
    Nexus Medicals, Greece


  • Frenasma
    Faran Laboratories, Greece


  • Fumarton
    Nippon Tenganyaku KenkyujoNitten, Japan


  • Fumarufen
    Nichi-Iko PharmaceuticalJMA, Japan


  • Fusachol
    Medisa Shinyaku, Japan


  • Gloditen
    Global Pharma, Bahrain; Global Pharma, Oman


  • H-Ketotifen
    Helcor, Romania


  • Hyalcrom
    Bausch & Lomb, Argentina


  • Intifen
    Interbat, Indonesia


  • Isocaren
    Pharmanel, Greece


  • Kathricol
    Mediapharm, Greece


  • Kedrop
    Grin, Mexico


  • Kenaler BPL
    BPL, Peru


  • Kenaler
    Ophtha, Colombia


  • Ketasma
    Sun, Bangladesh; Sun, India; Sun, Sri Lanka; Sun, Myanmar


  • Ketifen
    Acme, Bangladesh


  • Ketocev
    Cevallos, Argentina


  • Ketodil
    Techno, Bangladesh


  • Ketof
    Hexal, Czech Republic; Hexal, Germany; Hexal, Luxembourg; Hexal, Romania; IBN, Myanmar; Ibn Sina, Bangladesh


  • Ketofen
    Tabuk, Bahrain; Tabuk Pharmaceutical, Oman


  • Ketoftil
    Farmigea, Italy; Farmigea, Malta


  • Ketomar
    Incepta, Bangladesh


  • Ketoptic
    Oftalmi, Venezuela


  • Ketoten
    Sawai Seiyaku, Japan


  • Ketotif
    Delta, Bangladesh


  • Ketotifen Actavis
    Actavis, Latvia; Actavis, Netherlands; Balkanpharma, Bulgaria


  • Ketotifen AL
    Aliud, Czech Republic


  • Ketotifen CF
    Centrafarm, Netherlands


  • Ketotifen Fumarate
    Akorn, United States; Alcon, United States; Apotex, United States


  • Ketotifen PCH
    Pharmachemie, Netherlands


  • Ketotifen Ratiopharm
    ratiopharm, Netherlands


  • Ketotifen Sandoz
    Sandoz, Netherlands


  • Ketotifen Sopharma
    Sopharma, Bulgaria


  • Ketotifen Stada
    Stada, Germany


  • Ketotifen Teva
    Teva, Belgium


  • Ketotifen WZF Polfa
    WZF Polfa, Slovakia


  • Ketotifen
    Briz, Latvia; Magistra, Romania; Polfa Warszawa, Georgia; Polfa Warszawa, Poland; Sopharma, Georgia; Sopharma, Russian Federation; Toa Yakuhin, Japan


  • Ketotifeno MK
    Bonima, Costa Rica


  • Ketotilon
    Ohara Yakuhin, Japan


  • Ketotisan
    Wabosan, Austria


  • Klevistamin
    Kleva, Greece


  • Kofen
    Opsonin, Bangladesh


  • Labelphen
    Chrispa, Greece


  • Licoften
    Remedica, Bahrain; Remedica, Cyprus; Remedica, Oman


  • Magotiphen
    Tsuruhara Seiyaku, Japan


  • Mellabon
    Taiyo Pharmaceutical, Japan


  • Meni-Drops
    Pharmex, Greece


  • Minia
    Novo Healthcare, Bangladesh


  • Nichicard
    Nisshin Seiyaku - Yamagata, Japan


  • Nortifen
    Otto, Indonesia


  • Noxtor
    Rafarm, Greece


  • Orpidix
    Proel, Greece


  • Pädiatifen
    Pädia, Germany


  • Pellexeme
    Coup, Greece


  • Profilar
    United Pharmaceutical, United Arab Emirates; United Pharmaceutical, Bahrain; United Pharmaceutical, Iraq; United Pharmaceutical, Jordan; United Pharmaceutical, Libya; United Pharmaceutical, Oman; United Pharmaceutical, Qatar; United Pharmaceutical, Saudi Arabia; United Pharmaceutical, Sudan; United Pharmaceutical, Yemen


  • Profilas
    Dankos Laboratories, Indonesia


  • Profiten
    Pharma Clal, Israel


  • Prosma
    ACI, Bangladesh


  • Respimex
    Pfizer, Argentina


  • Sadifen
    Daito, Japan


  • Salatine
    Nipro PharmaNipurofama, Japan


  • Saldimen
    Tatsumi Kagaku, Japan


  • Scanditen
    Tempo Scan Pacific, Indonesia


  • Sekiton
    Kyorin Rimedio, Japan


  • Sosefen
    So.Se., Italy


  • Stafen
    Aristopharma, Bangladesh


  • Stamifen
    Pliva, Italy


  • Supdel
    Towa Yakuhin, Japan


  • Tenerel
    Medochemie, Bahrain; Medochemie, Cyprus; Medochemie, Iraq; Medochemie, Jordan; Medochemie, Sudan; Medochemie, Tanzania; Medochemie, Yemen


  • Tifen
    Pharmalliance, Algeria; Somatec, Bangladesh


  • Tofen
    Beximco, Bangladesh


  • Toma
    Navana, Bangladesh


  • Toti
    Eskayef, Bangladesh


  • Totifen
    Elpen, Greece


  • Zadec
    Novartis, Philippines


  • Zaditen
    Novartis, United Arab Emirates; Novartis, Argentina; Novartis, Austria; Novartis, Australia; Novartis, Belgium; Novartis, Bahrain; Novartis, Brazil; Novartis, Switzerland; Novartis, Chile; Novartis, Colombia; Novartis, Czech Republic; Novartis, Germany; Novartis, Denmark; Novartis, Ecuador; Novartis, Egypt; Novartis, Spain; Novartis, Finland; Novartis, France; Novartis, United Kingdom; Novartis, Ghana; Novartis, Greece; Novartis, Guyana; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Indonesia; Novartis, Ireland; Novartis, Israel; Novartis, Iraq; Novartis, Iran; Novartis, Iceland; Novartis, Italy; Novartis, Jordan; Novartis, Japan; Novartis, Kenya; Novartis, Kuwait; Novartis, Lebanon; Novartis, Lithuania; Novartis, Luxembourg; Novartis, Latvia; Novartis, Libya; Novartis, Malta; Novartis, Mexico; Novartis, Malaysia; Novartis, Nigeria; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Oman; Novartis, Philippines; Novartis, Poland; Novartis, Portugal; Novartis, Qatar; Novartis, Romania; Novartis, Russian Federation; Novartis, Saudi Arabia; Novartis, Sudan; Novartis, Singapore; Novartis, Syria; Novartis, Thailand; Novartis, Turkey; Novartis, Tanzania; Novartis, Venezuela; Novartis, South Africa; Novartis, Zimbabwe; Novartis Healthcare, Sweden; Novartis Ophthalmics, Hungary; Novartis Ophthalmics, Singapore; Novo Nordisk, Slovenia; Paladin, Canada; Sigma-tau, Germany; Zentiva, Slovakia


  • Zaditen SRO
    Defiante, Austria


  • Zaditoma
    Kyowa Yakuhin, Japan


  • Zaditor
    Novartis, Canada; Novartis, United States


  • Zaltifen
    Choseido Pharmaceutical, Japan


  • Zatin
    Shiba, Yemen


  • Zatotiten
    Kotobuki Seiyaku, Japan


  • Zetitec
    UCI, Brazil


  • Zikilion
    Nichi-Iko PharmaceuticalJMA, Japan

International Drug Name Search

Glossary

BANBritish Approved Name
BANMBritish Approved Name (Modified)
DCFDénomination Commune Française
DCITDenominazione Comune Italiana
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Wednesday, November 25, 2009

Mirtazapin Krka




Mirtazapin Krka may be available in the countries listed below.


Ingredient matches for Mirtazapin Krka



Mirtazapine

Mirtazapine is reported as an ingredient of Mirtazapin Krka in the following countries:


  • Denmark

  • Sweden

International Drug Name Search

Tuesday, November 24, 2009

Sedagul




Sedagul may be available in the countries listed below.


Ingredient matches for Sedagul



Lidocaine

Lidocaine hydrochloride (a derivative of Lidocaine) is reported as an ingredient of Sedagul in the following countries:


  • Switzerland

International Drug Name Search

Diabetnil




Diabetnil may be available in the countries listed below.


Ingredient matches for Diabetnil



Glibenclamide

Glibenclamide is reported as an ingredient of Diabetnil in the following countries:


  • Sri Lanka

International Drug Name Search

Sunday, November 22, 2009

Almadin




Almadin may be available in the countries listed below.


Ingredient matches for Almadin



Amlodipine

Amlodipine besilate (a derivative of Amlodipine) is reported as an ingredient of Almadin in the following countries:


  • South Africa

International Drug Name Search

Thursday, November 12, 2009

Ranitidine GenRx




Ranitidine GenRx may be available in the countries listed below.


Ingredient matches for Ranitidine GenRx



Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Ranitidine GenRx in the following countries:


  • Netherlands

International Drug Name Search

Tuesday, November 10, 2009

Magno Sanol uno




Magno Sanol uno may be available in the countries listed below.


Ingredient matches for Magno Sanol uno



Magnesium Oxide

Magnesium Oxide heavy (a derivative of Magnesium Oxide) is reported as an ingredient of Magno Sanol uno in the following countries:


  • Germany

International Drug Name Search

Monday, November 9, 2009

Oxandrin


Oxandrin is a brand name of oxandrolone, approved by the FDA in the following formulation(s):


OXANDRIN (oxandrolone - tablet; oral)



  • Manufacturer: SAVIENT PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 2.5MG [AB]


  • Manufacturer: SAVIENT PHARMS

    Approval date: November 5, 2001

    Strength(s): 10MG [RLD][AB]

Has a generic version of Oxandrin been approved?


A generic version of Oxandrin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Oxandrin and have been approved by the FDA:


oxandrolone tablet; oral



  • Manufacturer: PAR PHARM

    Approval date: June 22, 2007

    Strength(s): 10MG [AB], 2.5MG [AB]


  • Manufacturer: SANDOZ

    Approval date: December 1, 2006

    Strength(s): 10MG [AB], 2.5MG [AB]


  • Manufacturer: UPSHER SMITH

    Approval date: December 1, 2006

    Strength(s): 2.5MG [AB]


  • Manufacturer: UPSHER SMITH

    Approval date: March 22, 2007

    Strength(s): 10MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Oxandrin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Use of oxandrolone in the treatment of chronic obstructive pulmonary disease
    Patent 5,872,147
    Issued: February 16, 1999
    Inventor(s): Bowen; Robert E.
    Assignee(s): Bio-Technology General Corp.
    The subject invention provides a method of treating a symptom associated with chronic obstructive pulmonary disease in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of improving functional capacity and/or pulmonary function in a patient suffering from chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of an oxandrolone to the patient.
    Patent expiration dates:

    • December 5, 2017
      ✓ 
      Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS




  • Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
    Patent 6,090,799
    Issued: July 18, 2000
    Inventor(s): Berger; Joseph R.
    Assignee(s): BTG Pharmaceuticals Corp.
    A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
    Patent expiration dates:

    • July 18, 2017
      ✓ 
      Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS




  • Use of oxandrolone in the treatment of burns an other wounds
    Patent 6,576,659
    Issued: June 10, 2003
    Inventor(s): Don; Fishbein
    Assignee(s): Bio-Technology General Corp.
    The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Patent expiration dates:

    • December 5, 2017
      ✓ 
      Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS




  • Method for ameliorating muscle weakness/wasting in a patient infected with human immunodeficiency virus-type 1
    Patent 6,670,351
    Issued: December 30, 2003
    Inventor(s): Joseph R.; Berger
    Assignee(s): Bio-Technology General Corporation
    A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.
    Patent expiration dates:

    • October 20, 2012
      ✓ 
      Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS




  • Use of oxandrolone in the treatment of burns and other wounds
    Patent 6,828,313
    Issued: December 7, 2004
    Inventor(s): Don; Fishbein
    Assignee(s): Savient Pharmaceuticals, Inc.
    The subject invention provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The invention also provides a method of treating a wound in a patient suffering from a wound which comprises administering a therapeutically effective amount of an oxandrolone to the patient. The subject invention further provides a method of treating burn-induced weight loss in a burn patient which comprises administering a therapeutically effective amount of an oxandrolone in conjunction with a protein supplement to the patient.
    Patent expiration dates:

    • December 5, 2017
      ✓ 
      Patent use: TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS



See also...

  • Oxandrin Consumer Information (Wolters Kluwer)
  • Oxandrin Consumer Information (Cerner Multum)
  • Oxandrin AHFS DI Monographs (ASHP)
  • Oxandrolone Consumer Information (Wolters Kluwer)
  • Oxandrolone Consumer Information (Cerner Multum)
  • Oxandrolone AHFS DI Monographs (ASHP)

Thursday, November 5, 2009

Cholamid




Cholamid may be available in the countries listed below.


Ingredient matches for Cholamid



Hydroxymethylnicotinamide

Hydroxymethylnicotinamide is reported as an ingredient of Cholamid in the following countries:


  • Poland

International Drug Name Search

Monday, October 26, 2009

Monopril


Monopril is a brand name of fosinopril, approved by the FDA in the following formulation(s):


MONOPRIL (fosinopril sodium - tablet; oral)



  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: May 16, 1991

    Strength(s): 10MG [AB], 20MG [AB]


  • Manufacturer: BRISTOL MYERS SQUIBB

    Approval date: March 28, 1995

    Strength(s): 40MG [RLD][AB]

Has a generic version of Monopril been approved?


Yes. The following products are equivalent to Monopril:


fosinopril sodium tablet; oral



  • Manufacturer: APOTEX INC

    Approval date: May 17, 2005

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: AUROBINDO PHARMA LTD

    Approval date: March 30, 2011

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: INVAGEN PHARMS

    Approval date: April 20, 2005

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: RANBAXY

    Approval date: April 23, 2004

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: SANDOZ

    Approval date: April 23, 2004

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: TEVA

    Approval date: November 25, 2003

    Strength(s): 10MG [AB], 20MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: December 23, 2004

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: WATSON LABS

    Approval date: August 31, 2006

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]


  • Manufacturer: WATSON LABS FLORIDA

    Approval date: October 15, 2004

    Strength(s): 10MG [AB], 20MG [AB], 40MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Monopril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Monopril.

See also...

  • Monopril Consumer Information (Drugs.com)
  • Monopril Consumer Information (Wolters Kluwer)
  • Monopril Consumer Information (Cerner Multum)
  • Monopril Advanced Consumer Information (Micromedex)
  • Monopril AHFS DI Monographs (ASHP)
  • Fosinopril Consumer Information (Wolters Kluwer)
  • Fosinopril Consumer Information (Cerner Multum)
  • Fosinopril Advanced Consumer Information (Micromedex)
  • Fosinopril Sodium AHFS DI Monographs (ASHP)

Saturday, October 24, 2009

Norgesic


See also: Generic Norgesic Forte


Norgesic is a brand name of aspirin/caffeine/orphenadrine, approved by the FDA in the following formulation(s):


NORGESIC (aspirin; caffeine; orphenadrine citrate - tablet; oral)



  • Manufacturer: MEDICIS

    Approval date: October 27, 1982

    Strength(s): 385MG;30MG;25MG [AB]

Has a generic version of Norgesic been approved?


Yes. The following products are equivalent to Norgesic:


INVAGESIC (aspirin; caffeine; orphenadrine citrate tablet; oral)



  • Manufacturer: SANDOZ

    Approval date: November 27, 1996

    Strength(s): 385MG;30MG;25MG [AB]

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE (aspirin; caffeine; orphenadrine citrate tablet; oral)



  • Manufacturer: SANDOZ

    Approval date: December 31, 1996

    Strength(s): 385MG;30MG;25MG [AB]


  • Manufacturer: STEVENS J

    Approval date: April 30, 1999

    Strength(s): 385MG;30MG;25MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Norgesic. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Norgesic.

See also...

  • Norgesic Consumer Information (Cerner Multum)
  • Norgesic Advanced Consumer Information (Micromedex)
  • Orphenadrine/Aspirin/Caffeine Consumer Information (Wolters Kluwer)
  • Aspirin/caffeine/orphenadrine Consumer Information (Cerner Multum)
  • Orphenadrine w/A.C. Advanced Consumer Information (Micromedex)
  • Orphenadrine, aspirin, and caffeine Advanced Consumer Information (Micromedex)

Friday, October 23, 2009

Tolmin




Tolmin may be available in the countries listed below.


Ingredient matches for Tolmin



Mianserin

Mianserin hydrochloride (a derivative of Mianserin) is reported as an ingredient of Tolmin in the following countries:


  • Denmark

International Drug Name Search

Thursday, October 22, 2009

Prozac Weekly


See also: Generic Prozac


Prozac Weekly is a brand name of fluoxetine, approved by the FDA in the following formulation(s):


PROZAC WEEKLY (fluoxetine hydrochloride - capsule, delayed rel pellets; oral)



  • Manufacturer: LILLY

    Approval date: February 26, 2001

    Strength(s): EQ 90MG BASE [RLD][AB]

Has a generic version of Prozac Weekly been approved?


A generic version of Prozac Weekly has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Prozac Weekly and have been approved by the FDA:


fluoxetine hydrochloride capsule, delayed rel pellets; oral



  • Manufacturer: BARR

    Approval date: March 24, 2010

    Strength(s): EQ 90MG BASE [AB]


  • Manufacturer: DR REDDYS LABS LTD

    Approval date: March 22, 2010

    Strength(s): EQ 90MG BASE [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Prozac Weekly. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Fluoxetine enteric pellets and methods for their preparation and use
    Patent 5,910,319
    Issued: June 8, 1999
    Inventor(s): Anderson; Neil R. & Harrison; Roger G. & Lynch; Daniel F. & Oren; Peter L.
    Assignee(s): Eli Lilly and Company
    A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
    Patent expiration dates:

    • May 29, 2017
      ✓ 
      Patent use: METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION




  • Method for the treatment of CNS disorders
    Patent 5,985,322
    Issued: November 16, 1999
    Inventor(s): Anderson; Neil R. & Harrison; Roger F. & Lynch; Daniel F. & Oren; Peter L.
    Assignee(s): Eli Lilly and Company
    An improved method for the treatment of central nervous system disorders comprises treating patients with an enteric fluoxetine formulation.
    Patent expiration dates:

    • May 29, 2017
      ✓ 
      Patent use: METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA




  • Fluoxetine enteric pellets and methods for their preparation and use
    Patent RE39030
    Issued: March 21, 2006
    Inventor(s): Anderson; Neil Robert & Harrison; Roger Garrick & Lynch; Daniel Frederick & Oren; Peter Lloyd
    Assignee(s): Eli Lilly and Company
    A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
    Patent expiration dates:

    • May 29, 2017
      ✓ 
      Patent use: METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
      ✓ 
      Drug product


    • May 29, 2017
      ✓ 
      Patent use: METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
      ✓ 
      Drug product



See also...

  • Prozac Weekly Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Prozac Weekly Consumer Information (Cerner Multum)
  • Prozac Weekly Advanced Consumer Information (Micromedex)
  • Fluoxetine Consumer Information (Drugs.com)
  • Fluoxetine Consumer Information (Wolters Kluwer)
  • Fluoxetine Delayed-Release Capsules Consumer Information (Wolters Kluwer)
  • Fluoxetine Solution Consumer Information (Wolters Kluwer)
  • Fluoxetine Consumer Information (Cerner Multum)
  • Alti-Fluoxetine Hydrochloride Advanced Consumer Information (Micromedex)
  • Phl-Fluoxetine Advanced Consumer Information (Micromedex)
  • Fluoxetine Advanced Consumer Information (Micromedex)
  • Fluoxetine Hydrochloride AHFS DI Monographs (ASHP)

Sunday, October 18, 2009

Ophthaine


See also: Generic Ophthetic


Ophthaine is a brand name of proparacaine ophthalmic, approved by the FDA in the following formulation(s):


OPHTHAINE (proparacaine hydrochloride - solution/drops; ophthalmic)



  • Manufacturer: APOTHECON

    Approved Prior to Jan 1, 1982

    Strength(s): 0.5% [RLD][AT]

Has a generic version of Ophthaine been approved?


Yes. The following products are equivalent to Ophthaine:


ALCAINE (proparacaine hydrochloride solution/drops; ophthalmic)



  • Manufacturer: ALCON

    Approved Prior to Jan 1, 1982

    Strength(s): 0.5% [AT]

proparacaine hydrochloride solution/drops; ophthalmic



  • Manufacturer: BAUSCH AND LOMB

    Approval date: September 29, 1995

    Strength(s): 0.5% [AT]


  • Manufacturer: TAYLOR PHARMA

    Approval date: March 16, 2000

    Strength(s): 0.5% [AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ophthaine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Ophthaine.

See also...

  • Proparacaine Drops Consumer Information (Wolters Kluwer)
  • Proparacaine Ophthalmic Advanced Consumer Information (Micromedex)

Melodyn




Melodyn may be available in the countries listed below.


Ingredient matches for Melodyn



Meloxicam

Meloxicam is reported as an ingredient of Melodyn in the following countries:


  • Hungary

  • Slovakia

International Drug Name Search

Friday, October 16, 2009

Papaverin Hydrochloric




Papaverin Hydrochloric may be available in the countries listed below.


Ingredient matches for Papaverin Hydrochloric



Papaverine

Papaverine hydrochloride (a derivative of Papaverine) is reported as an ingredient of Papaverin Hydrochloric in the following countries:


  • Georgia

International Drug Name Search

Tuesday, October 13, 2009

Coagulation Factor XIII, Human




ATC (Anatomical Therapeutic Chemical Classification)

B02BD07

CAS registry number (Chemical Abstracts Service)

0009013-56-3

Therapeutic Categories

Hemostatic agent

Blood coagulation factor substitute

Foreign Names

  • Factor XIII coagulationis sanguinis humanus (Latin)
  • Blutgerinnungsfaktor XIII vom Menschen (German)
  • Facteur XIII de coagulation humain (French)

Generic Names

  • Fibrinase (IS)
  • Fibrin-stabilizing factor (IS: FSF)
  • FSF (IS)
  • Laki-Lorand factor (IS: LLF)
  • LLF (IS)

Brand Names

  • Beriplast P
    CSL Behring, Japan


  • Beriplast
    CSL Behring, Japan


  • Bolheal
    Chemo-Sero-Therapeutic Research InstitutKaketsuken, Japan


  • Fibrogammin
    Aventis Behring, Israel; CSL Behring, Germany; ZLB Behring, Belgium


  • Fibrogammin P
    Aventis, Argentina; Aventis Behring, Israel; CSL Behring, Austria; CSL Behring, Switzerland; CSL Behring, United Kingdom; CSL Behring, Japan; CSL Behring, Luxembourg; ZLB Behring, Hong Kong


  • Tisseel (Coagulation Factor XIII, Human and Fibrinogen)
    Baxter, Austria

International Drug Name Search

Glossary

ISInofficial Synonym

Click for further information on drug naming conventions and International Nonproprietary Names.

Monday, October 12, 2009

Ansi




Ansi may be available in the countries listed below.


Ingredient matches for Ansi



Fluoxetine

Fluoxetine hydrochloride (a derivative of Fluoxetine) is reported as an ingredient of Ansi in the following countries:


  • Indonesia

International Drug Name Search

Sunday, October 11, 2009

Amoxicilline Zydus




Amoxicilline Zydus may be available in the countries listed below.


Ingredient matches for Amoxicilline Zydus



Amoxicillin

Amoxicillin trihydrate (a derivative of Amoxicillin) is reported as an ingredient of Amoxicilline Zydus in the following countries:


  • France

International Drug Name Search

Sunday, October 4, 2009

Erisol




Erisol may be available in the countries listed below.


Ingredient matches for Erisol



Erythromycin

Erythromycin is reported as an ingredient of Erisol in the following countries:


  • Argentina

International Drug Name Search